From Science to Signals: SEC Enforcement, Predictive Markets, and Informational Advantage in Life Sciences

SEC enforcement in the life sciences sector has not simply intensified—it has fundamentally changed in character. What regulators are focused on today is no longer confined to clear cases of misconduct, such as trading on a known FDA outcome or making an objectively false statement. Instead, enforcement has evolved to reflect the way this industry actually functions: that is, through the continuous creation, interpretation, and use of probabilistic information about uncertain outcomes. At the same time, enforcement in this space has become more visible and more consequential. Insider trading remains a core priority area for the SEC—particularly in sectors like life sciences, where market-moving events are discrete, predictable, and highly material. What has changed is not only the scope of the conduct being scrutinized, but the SEC’s ability to identify and pursue it.

At its core, the shift is about informational advantage.

Life sciences companies operate in a system where value is driven by a series of binary events—clinical readouts, regulatory decisions by agencies such as the FDA and other global regulators, including approvals, non‑approvals (e.g., Complete Response Letters), and related determinations. But the information that underlies those events does not emerge all at once. It develops gradually, often ambiguously, and is refined over time through analysis, internal debate, and regulatory interaction. Long before any formal announcement is made, people inside the organization—and increasingly, those connected to it—begin to form views about direction and likelihood. Historically, that type of evolving insight might have been viewed as “too preliminary” to matter legally. That is no longer the case.

From an enforcement perspective today, information does not need to be final to be material. If it meaningfully shifts how a reasonable investor would assess the probability of an outcome, it can already fall within the scope of concern. This simple but powerful reframing moves risk earlier in the information lifecycle and expands it across a broader set of actors.

From Knowledge to Prediction

This evolution has reshaped insider trading doctrine in a way that is particularly significant for life sciences companies. The traditional model—trading on a definitive, nonpublic fact—still exists, but it is no longer the boundary of enforcement. Increasingly, the focus is on whether an individual had a predictive edge over the market.

This shift has coincided with a sustained emphasis by the SEC on insider trading enforcement as a priority area. While the legal theories have evolved, so too has the frequency with which the SEC brings cases built around event-driven trading, inference-based conduct, and patterns of repeated success ahead of regulatory milestones. In the life sciences space, when those milestones are clearly defined and closely tracked, this enforcement focus is particularly pronounced.

In a sector built on uncertainty, that edge often comes not from explicit knowledge, but from position and perspective. A clinical scientist observing emerging efficacy trends, a regulatory professional interpreting the tone of FDA feedback, a data analyst identifying directional shifts in trial results—all may be able to form a more accurate view of the likely outcome than the market, even in the absence of certainty. That reality expands exposure far beyond the executive suite. Informational advantage is distributed across organizations—within clinical teams, regulatory functions, data groups, and other operational roles—and extends outward to consultants, advisors, CROs, and expert networks. It also extends beyond the company itself, as insight about one program can inform trading in competitors or the same or related therapeutic areas. What matters, increasingly, is not whether someone “knew” the answer, but whether they were better positioned to infer it.

Disclosure in a World of Uncertainty

If insider trading risk focuses on how information is used by individuals, disclosure risk reflects how that same evolving information is presented to the market. Here, the challenge is not typically one of falsity. It is one of alignment. Regulators are asking whether a company’s external messaging fairly reflects its internal understanding at the time it communicates. That is a deceptively difficult standard in life sciences. Internally, information is provisional and not uniformly shared across companies. Data evolves. Regulatory feedback is nuanced and iterative. Reasonable experts may disagree. At the same time, companies face very real pressures: the need to raise capital, maintain investor confidence, and communicate progress in a highly competitive environment.

Against that backdrop, risk tends to arise not from obvious misstatements, but from imbalance—when positive developments are highlighted while uncertainties or constraints are left implicit or underemphasized. These are the cases that, in hindsight, become framed as misleading by omission. The difficulty, as companies often experience it, is that decisions made in good faith within a scientific and regulatory context are later evaluated through a securities law lens that is both retrospective and investor focused.

The Emergence of Predictive Systems and Markets

Overlaying these traditional areas of risk is a powerful and accelerating development: the rise of predictive analytics and prediction markets. Market participants are no longer simply reacting to disclosures. They are increasingly anticipating them. By aggregating historical data, regulatory patterns, timing signals, and industry inputs, they are building models that generate probabilistic forecasts of outcomes—approval likelihoods, trial success rates, regulatory timelines. Prediction markets take this one step further. They convert those probabilistic views into direct, tradable positions on events. Rather than speculating indirectly through equities, participants can express views explicitly on whether a drug will be approved, whether a trial will succeed, or whether a milestone will be met. Prices in these markets become a real-time reflection of collective expectations.

For companies, this has two important implications. First, their internal signals—clinical developments, regulatory interactions, changes in timing—are increasingly embedded in external market expectations before formal disclosure occurs. Even without any explicit information leak, the aggregation of partial signals can produce insights that resemble insider knowledge. Second, and more fundamentally, predictive systems challenge the traditional boundary of insider trading. If no single piece of information is clearly material nonpublic information, but the combination of those inputs produces a highly accurate prediction, where does liability begin? Regulators are not answering that question narrowly. The direction of travel suggests that the distinction between having inside information and being able to predict outcomes with high confidence is narrowing. That principle applies equally to traditional securities trading and to emerging event-based markets.

For companies, this means that internal developments are no longer confined to internal decision-making or future disclosures. Instead, they are increasingly reflected—indirectly but meaningfully—in external models, expectations, and market behavior before any formal announcement is made. This convergence is significant for enforcement. As predictive analytics and prediction markets become more sophisticated, they generate structured, repeatable trading behavior tied to identifiable events. Those patterns—rather than isolated trades—are precisely what modern SEC tools are designed to detect. As a result, the growth of predictive markets does not sit outside the enforcement framework; it amplifies the visibility of informational advantage and its use in trading.

One Set of Facts, Multiple Regulators

At the same time, companies are navigating this environment under the scrutiny of multiple regulators operating in parallel. The FDA governs the scientific and regulatory process, often relying on confidentiality and controlled communication. The SEC evaluates disclosure and market fairness. The DOJ may overlay criminal enforcement. And as prediction markets and event-based instruments grow, additional regulatory bodies are becoming relevant.

These regimes do not operate in isolation. They apply different expectations to the same underlying facts. What is appropriate from a regulatory or scientific perspective—caution, iteration, and evolving or preliminary disclosures—may later be viewed through a securities framework that prioritizes transparency and investor understanding. This creates a persistent tension that companies acutely feel: they are making reasonable, context-driven decisions in real time, knowing those decisions may later be judged with the benefit of hindsight.

The Visibility of Modern Enforcement

Compounding these dynamics is the way enforcement cases are now built. Detection is no longer only dependent on whistleblowers or obvious misconduct. It is driven by data. The SEC now operates with highly advanced analytical tools that can:

• Correlate trading activity with clinical and regulatory timelines
• Identify statistically improbable returns ahead of events
• Detect repeated success patterns across multiple transactions
• Map networks of individuals and related accounts

These capabilities allow the SEC to build cases based not only on direct evidence of a tip, but on patterns, probabilities, and relationships. Regulators can identify:

• Repeated success ahead of events
• Concentrated trading activity near milestones
• Relationships among individuals and entities

In this environment, predictive and event-driven trading strategies—because they are systematic and repeatable—can be more visible, not less. This is a critical point: the expansion of insider trading theories to include probabilistic and inference-based conduct has been made practical by these improved detection capabilities. What might previously have been too difficult to identify or prove is now increasingly observable and actionable.

From Compliance Problem to Governance Challenge

Despite the complexity of this environment, the most important point is often overlooked: this is not an uncontrollable risk. In practice, the companies that are most effective in managing it do not treat it as a narrow compliance issue. They treat it as an information governance challenge. They recognize that the central question is not simply who has material nonpublic information, but:

When informational advantage arises, how it develops, who has access to it, and how it moves—both within the organization and into the market.

That leads to a different set of actions. They map the lifecycle of information from early signals through interpretation and disclosure. They expand their conception of MNPI to include probabilistic insight and regulatory context. They design controls around real inflection points rather than static calendars. They integrate clinical, regulatory, legal, and investor perspectives into disclosure decisions. They manage consultant and third-party exposure as actively as internal risk. And increasingly, they begin to address predictive analytics and market dynamics explicitly, rather than treating them as externalities. Just as importantly, they invest in ensuring that their people understand the environment they are operating in—particularly the idea that having an informational edge, even without certainty, can create exposure.

Final Perspective

Taken together, these developments point to a single unifying reality. Life sciences companies operate in a system defined by uncertainty, interpretation, timing, and prediction. Regulators now evaluate that system through a lens of informational advantage, market fairness, and investor impact. Meanwhile, predictive analytics, improved detection tools, and emerging prediction markets are accelerating both the formation of market expectations and the ability of regulators to observe how those expectations are traded upon. The result is that the line between knowing and predicting is becoming increasingly thin.

Final Takeaway

The companies that navigate this environment successfully are not those that attempt to avoid or suppress information. They cannot. Scientific progress depends on generating, interpreting, and sharing it.

Instead, they are the companies that:

• Understand where informational advantage originates;
• Control how it flows across people, systems, and external actors;
• Align internal understanding with external communication;
• Recognize how predictive analytics and prediction markets amplify and transmit their signals;
• Account for the reality that enforcement is both more focused on insider trading and more capable of detecting it; and
• Equip their employees and partners to operate responsibly within a probabilistic world.

Because ultimately:  This is not just a question of compliance.  It is a question of how to govern information in a market where prediction itself is increasingly visible, actionable, and regulated.

To receive the latest insights on US legal developments, subscribe to the Freshfields A Fresh Take Blog.